



SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

March 29, 2024 11:15 AM EDT

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

March 29, 2024

SAB-142 Phase 1 trial on track for data release during 2024

Completed financing for up to \$110 million with leading life science investors

Cash and equivalents of \$56.6 million as of December 31, 2023

Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026

Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (Nasdaq:SABS), (“SAB” or “the company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hlgG) for delaying the onset or progression of Type 1 diabetes (T1D), today announced its financial results for the fourth quarter of 2023 in addition to its full year financial results for the fiscal year ended December 31, 2023, and reported on recent accomplishments and expected upcoming milestones.

“During 2023, we significantly changed the direction of our company to focus on SAB-142, our innovative, human anti-thymocyte immune globulin for the prevention of progression of T1D” stated Samuel J. Reich, Chairman and CEO of SAB. “Our pivot to SAB-142 catalyzed our capital raise of up to \$110 million, led by a dedicated group of specialist investors, many of whom have deep knowledge about the needs of patients with T1D. We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need. Despite recent advances in therapy, there remains a meaningful void for therapies that can prevent the progression of this devastating illness. We remain on track to provide Phase 1 data for SAB-142 by the end of 2024.”

Highlights from 4Q23 and Recent Corporate Developments

- Closed an equity financing for up to \$110 million with leading life sciences investors, generating funds sufficient for operations into 2026 assuming the exercise of all outstanding Tranche B Warrants.
- Initiated a Phase 1 clinical trial of SAB-142 for safety and tolerability in autoimmune disorders including T1D.
- Announced Michael G. King Jr. as new Chief Financial Officer. Mr. King has extensive experience and prior success as an award-winning biotechnology research analyst and senior advisor with more than 25 years of experience with investors, banking institutions and thought leaders in various pharmaceutical disciplines.
- Appointed Andrew Moin, Partner and Analyst at Sessa Capital, a New York based investment advisor registered with the SEC, to the SAB Board of Directors. Mr. Moin has been with Sessa since 2012, where he works on idea generation, research, and investment implementation. He has also been deeply involved in the type 1 diabetes community for over 20 years, including as a volunteer and member of the Young Leadership Committee of the New York City Chapter of the JDRF and an early supporter of multiple fundamental diabetes research and innovation projects.
- Appointed Katie Ellias, Managing Partner at JDRF T1D Fund, to the SAB Board of Directors. The JDRF T1D Fund LLC is a venture philanthropy fund with approximately \$200 million in assets, including an investment in SAB. Ms. Ellias joined the T1D Fund in 2018 where she has led several investments in companies developing T1D-oriented therapies. She has also served as a director on the board of several companies, including, DiogenX, Veralox

Therapeutics, i2O Therapeutics, and Capillary Biomedical.

- Welcomed Erick Lucera to our Board of Directors. Mr. Lucera, a 30-year veteran of the biotechnology and medical device industry, has held executive positions at several healthcare companies, most recently as Chief Financial Officer of Editas Medicine.
- Hosted 2023 R&D Day virtual and in-person events, affirming SAB's strategic focus in the autoimmunity space with SAB-142, a disease-modifying fully human hIgG aimed at preventing onset or disease progression of Type 1 Diabetes, and subsequently can be expanded into other immunology indications.

Upcoming Corporate Presentation

Samuel J. Reich, Chairman and CEO of SAB Biotherapeutics, will present on behalf of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024, at 1:30 pm ET. The company will also participate in virtual 1:1 meetings. A replay of Mr. Reich's presentation will be archived on the SAB Biotherapeutics website for up to one year.

Fiscal Year 2023 Financial Results

- SAB Biotherapeutics held cash and equivalents of \$56.6 million at December 31, 2023, compared to \$15.0 million at December 31, 2022.
- R&D expenses of \$16.5 million and \$36.4 million for the years ended December 31, 2023 and December 31, 2022 respectively.
- General and administrative expenses of \$23.8 million and \$16.4 million for the years ended December 31, 2023 and December 31, 2022 respectively.
- Other net expense of \$4.1 million for the year ended December 31, 2023, and net other income of \$10.2 million for the year ended December 31, 2022.
- SAB reported a net loss of \$42.2 million and \$18.7 million for the years ended December 31, 2023 and December 31, 2022 respectively.

2024 Cash Guidance

The company believes it has sufficient current and future cash via the exercise of all outstanding Tranche B warrants sufficient to fund its operations into 2026.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomal (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB's DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: <https://www.SAB.bio/> and follow SAB on Twitter and LinkedIn.

Forward-Looking Statements

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "to be," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our T1D program, and other discovery programs, the funding of the tranche B warrants issued in the Company's private placement offering, financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government, and other third-party collaborations or funded programs.

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry's results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned "Risk Factors" in our most recent annual report on Form 10-K, as amended, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities

and Exchange Commission, which are available at <https://www.sec.gov>. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

SAB Biotherapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets

	<u>December 31,</u> <u>2023</u>	<u>December 31,</u> <u>2022</u>
Assets		
Current assets		
Cash and cash equivalents	\$ 56,566,066	\$ 15,046,894
Accounts receivable, net	—	5,556,577
Prepaid expenses and other current assets	2,340,797	1,493,982
Total current assets	58,906,863	22,097,453
Long-term prepaid insurance	350,230	467,694
Operating lease right-of-use assets	1,277,982	1,192,054
Financing lease right-of-use assets	3,669,659	3,896,873
Property, plant and equipment, net	19,736,519	23,250,853
Total assets	\$ 83,941,253	\$ 50,904,927
Liabilities and Stockholders' Equity		
Current liabilities		
Accounts payable	\$ 945,927	\$ 3,679,116
Notes payable	1,050,849	772,665
Operating lease liabilities, current portion	669,946	490,794
Finance lease liabilities, current portion	132,004	132,788
Deferred grant income	1,322,410	—
Accrued expenses and other current liabilities	6,692,181	9,917,981
Total current liabilities	10,813,317	14,993,344
Operating lease liabilities, noncurrent	635,777	361,225
Finance lease liabilities, noncurrent	3,418,483	3,629,642
Warrant liabilities	11,774,235	320,930
Notes payable, noncurrent	—	541,644
Total liabilities	26,641,812	19,846,785
Commitments and contingencies (Note 17)		
Stockholders' equity		
Preferred stock; \$0.0001 par value; 10,000,000 shares authorized, 42,236 shares issued and outstanding at December 31, 2023 and 0 shares issued and outstanding at December 31, 2022, respectively	5	—
Common stock; \$0.0001 par value; 800,000,000 shares authorized at December 31, 2023 and December 31, 2022; 9,280,159 and 5,094,901 shares issued, respectively, and 9,225,494 and 5,040,236 outstanding at December 31, 2023 and December 31, 2022, respectively	929	510
Treasury stock, at cost; 54,665 shares held at December 31, 2023 and 2022	(5,521,246)	(5,521,246)
Additional paid-in capital	152,856,874	84,448,633
Accumulated other comprehensive income	26,420	—
Accumulated deficit	(90,063,541)	(47,869,755)
Total stockholders' equity	57,299,441	31,058,142
Total liabilities and stockholders' equity	\$ 83,941,253	\$ 50,904,927

**The consolidated balance sheets' common stock share amounts have been retroactively adjusted to account for the Company's 1:10 Reverse Stock Split, effective January 5, 2024.*

See accompanying notes to the consolidated financial statements.

SAB Biotherapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss

	For The Year Ended December 31,	
	2023	2022
Revenue		
Grant revenue	\$ 2,238,991	\$ 23,904,181
Total revenue	<u>2,238,991</u>	<u>23,904,181</u>
Operating expenses		
Research and development	16,515,005	36,438,513
General and administrative	23,799,306	16,383,285
Total operating expenses	<u>40,314,311</u>	<u>52,821,798</u>
Loss from operations	(38,075,320)	(28,917,617)
Other income (expense)		
Changes in fair value of warrant liabilities	(4,823,237)	10,399,200
Interest expense	(315,284)	(301,584)
Interest income	584,966	71,072
Other income	435,089	33,754
Total other income (expense)	<u>(4,118,466)</u>	<u>10,202,442</u>
Loss before income taxes	(42,193,786)	(18,715,175)
Income tax expense (benefit)	—	25,629
Net loss	<u>\$ (42,193,786)</u>	<u>\$ (18,740,804)</u>
Other comprehensive loss:		
Foreign currency translation	\$ 26,420	—
Total comprehensive loss	<u>\$ (42,167,366)</u>	<u>\$ (18,740,804)</u>
Loss per common share attributable to the Company's shareholders		
Basic and diluted loss per common share	\$ (7.64)	\$ (4.31)
Weighted-average common shares outstanding – basic and diluted	5,521,487	4,352,497

**The consolidated statements of operations and comprehensive loss's share and per share amounts have been retroactively adjusted to account for the Company's 1:10 Reverse Stock Split, effective January 5, 2024.*

See accompanying notes to the consolidated financial statements.

Contacts

Media Relations: khollon@sab.bio

Investor Relations: matt@milestone-advisorsllc.com

Media Relations: khollon@sab.bio

Investor Relations: matt@milestone-advisorsllc.com



Source: SAB Biotherapeutics, Inc.